Literature DB >> 20629135

Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations.

Philippe Huot1, Tom H Johnston, Tayyeba Darr, Lili-Naz Hazrati, Naomi P Visanji, Donna Pires, Jonathan M Brotchie, Susan H Fox.   

Abstract

Well-formed visual hallucinations (VH) are common in patients with Parkinson's disease (PD). The pathophysiology of VH in PD is unknown but may involve structures mediating visual processing such as the inferior temporal cortex. Serotonergic type 2A (5-HT(2A)) receptors have been linked to many psychiatric disorders, including psychosis. We hypothesized that enhanced 5-HT(2A) receptor levels may be involved in VH in PD. Autoradiographic binding using [(3)H]-ketanserin and spiperone, to define 5-HT(2A) receptors, was performed in 6 PD patients with VH, 6 PD patients without VH, and 5 healthy, age-matched controls. The cerebral regions studied included the orbitofrontal cortex, inferolateral temporal cortex, motor cortex, striatum, and substantia nigra. There was a significant (45.6%) increase in the levels of [(3)H]-ketanserin binding in the inferolateral temporal cortex of PD patients with VH when compared with PD patients without VH (54.3 +/- 5.2 fmol/mg vs. 37.3 +/- 4.3 fmol/mg, P = 0.039). Additionally, there was a significant increase in the levels of 5-HT(2A) receptors in the motor cortex of all PD patients taken as a group when compared with controls (57.8 +/- 5.7 fmol/mg vs. 41.2 +/- 2.6 fmol/mg, P = 0.0297). These results suggest that enhanced 5-HT(2A)-mediated neurotransmission in the inferolateral temporal cortex, a critical structure in visual processing, might be associated with the development of VH in PD. Our results provide new insights into the pathophysiology of VH in PD and provide an anatomical basis to explain why compounds with 5-HT(2A) antagonist activity are effective at alleviating this debilitating complication. (c) 2010 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20629135     DOI: 10.1002/mds.23083

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  39 in total

Review 1.  An update expert opinion on management and research strategies in Parkinson's disease psychosis.

Authors:  Jennifer G Goldman; Christina L Vaughan; Christopher G Goetz
Journal:  Expert Opin Pharmacother       Date:  2011-06-02       Impact factor: 3.889

2.  Successful treatment of intractable visual hallucinations with 5-HT 2A antagonist ketanserin.

Authors:  Iris E C Sommer; Hidde Kleijer; Lucy Visser; Teus van Laar
Journal:  BMJ Case Rep       Date:  2018-06-27

Review 3.  Parkinson's disease: the quintessential neuropsychiatric disorder.

Authors:  Daniel Weintraub; David J Burn
Journal:  Mov Disord       Date:  2011-05       Impact factor: 10.338

4.  Progress Regarding Parkinson's Disease Psychosis: It's No Illusion.

Authors:  Daniel Weintraub
Journal:  Mov Disord Clin Pract       Date:  2016-08-11

Review 5.  5-HT2A blockade for dyskinesia and psychosis in Parkinson's disease: is there a limit to the efficacy of this approach? A study in the MPTP-lesioned marmoset and a literature mini-review.

Authors:  Cynthia Kwan; Imane Frouni; Dominique Bédard; Stephen G Nuara; Jim C Gourdon; Adjia Hamadjida; Philippe Huot
Journal:  Exp Brain Res       Date:  2018-11-15       Impact factor: 1.972

Review 6.  The neurobiological basis of cognitive impairment in Parkinson's disease.

Authors:  Glenda M Halliday; James B Leverenz; Jay S Schneider; Charles H Adler
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

Review 7.  Pathophysiology of dyskinesia and behavioral disorders in non-human primates: the role of serotonergic fibers.

Authors:  Véronique Sgambato; Léon Tremblay
Journal:  J Neural Transm (Vienna)       Date:  2018-03-03       Impact factor: 3.575

8.  Treatment of psychosis and dementia in Parkinson's disease.

Authors:  Jennifer G Goldman; Samantha Holden
Journal:  Curr Treat Options Neurol       Date:  2014-03       Impact factor: 3.598

Review 9.  Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis.

Authors:  Shyam C Panchal; William G Ondo
Journal:  Curr Psychiatry Rep       Date:  2018-01-27       Impact factor: 5.285

Review 10.  Recent advances in the neuropsychopharmacology of serotonergic hallucinogens.

Authors:  Adam L Halberstadt
Journal:  Behav Brain Res       Date:  2014-07-15       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.